Expression of LDL-A module of relaxin receptor in prostate cancer cells inhibits tumorigenesis

International Journal of Oncology

Volumn 39, Issue 6, 2011, Pages 1559-1565

  Feng, Shu ^a   Agoulnik, Alexander I ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

LDL A; Prostate cancer; Relaxin receptor

Indexed keywords

CALVASCULIN; GELATINASE A; HORMONE RECEPTOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN A; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 28; MUCIN 1; PROTEIN KINASE B; PROTEIN S 100; PROTEIN S100P; RELAXIN; RXFP1 PROTEIN; SOMATOMEDIN BINDING PROTEIN 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CARCINOGENESIS; CELL ADHESION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIPOPROTEIN(A); MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, PEPTIDE; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80054812700     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1159     Document Type: Article

References (28)

1. Sherwood OD: Relaxin's physiological roles and other diverse actions. Endocr Rev 25: 205-234, 2004.
2. Bathgate RA, Ivell R, Sanborn BM, Sherwood OD and Summers RJ: International Union of Pharmacology LVII: recommendations for the nomenclature of receptors for relaxin family peptides. Pharmacol Rev 58: 7-31, 2006.
3. Agoulnik AI: Relaxin and related peptides in male reproduction. Adv Exp Med Biol 612: 49-64, 2007.
4. Hsu SY, Nakabayashi K, Nishi S, et al.: Activation of orphan receptors by the hormone relaxin. Science 295: 671-674, 2002. (Pubitemid 34111824)
5. Zhao L, Roche PJ, Gunnersen JM, et al.: Mice without a functional relaxin gene are unable to deliver milk to their pups. Endocrinology 140: 445-453, 1999. (Pubitemid 29011190)
6. Krajnc-Franken MA, van Disseldorp AJ, Koenders JE, Mosselman S, van Duin M and Gossen JA: Impaired nipple development and parturition in LGR7 knockout mice. Mol Cell Biol 24: 687-696, 2004. (Pubitemid 38057920)
7. Kamat AA, Feng S, Bogatcheva NV, Truong A, Bishop CE and Agoulnik AI: Genetic targeting of relaxin and insulin-like factor 3 receptors in mice. Endocrinology 145: 4712-4720, 2004. (Pubitemid 39281465)
8. Samuel CS, Hewitson TD, Unemori EN and Tang ML: Drugs of the future: the hormone relaxin. Cell Mol Life Sci 64: 1539-1557, 2007. (Pubitemid 46954152)
9. Jeyabalan A, Shroff SG, Novak J and Conrad KP: The vascular actions of relaxin. Adv Exp Med Biol 612: 65-87, 2007.
10. Vinall RL, Tepper CG, Shi XB, Xue LA, Gandour-Edwards R and de Vere White RW: The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7. Oncogene 25: 2082-2093, 2006.
11. Silvertown JD, Ng J, Sato T, Summerlee AJ and Medin JA: H2 relaxin overexpression increases in vivo prostate xenograft tumor growth and angiogenesis. Int J Cancer 118: 62-73, 2006. (Pubitemid 41681581)
12. Thompson VC, Morris TG, Cochrane DR, et al.: Relaxin becomes upregulated during prostate cancer progression to androgen independence and is negatively regulated by androgens. Prostate 66: 1698-1709, 2006. (Pubitemid 44893896)
13. Feng S, Agoulnik IU, Bogatcheva NV, et al.: Relaxin promotes prostate cancer progression. Clin Cancer Res 13: 1695-1702, 2007. (Pubitemid 46952934)
14. Silvertown JD, Symes JC, Neschadim A, et al.: Analog of H2 relaxin exhibits antagonistic properties and impairs prostate tumor growth. FASEB J 21: 754-765, 2007. (Pubitemid 46348251)
15. Liu S, Vinall RL, Tepper C, et al.: Inappropriate activation of androgen receptor by relaxin via beta-catenin pathway. Oncogene 27: 499-505, 2008.
16. Thompson VC, Hurtado-Coll A, Turbin D, et al.: Relaxin drives Wnt signaling through upregulation of PCDHY in prostate cancer. Prostate 70: 1134-1145, 2010.
17. Feng S, Agoulnik IU, Truong A, et al.: Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. Endocr Relat Cancer 17: 1021-1033, 2010.
18. Kong RC, Shilling PJ, Lobb DK, Gooley PR and Bathgate RA: Membrane receptors: structure and function of the relaxin family peptide receptors. Mol Cell Endocrinol 320: 1-15, 2010.
19. Scott DJ, Layfield S, Yan Y, et al.: Characterization of novel splice variants of LGR7 and LGR8 reveals that receptor signaling is mediated by their unique low density lipoprotein class A modules. J Biol Chem 281: 34942-34954, 2006. (Pubitemid 46036533)
20. de Souza PL, Russell PJ and Kearsley J: Role of the Akt pathway in prostate cancer. Curr Cancer Drug Targets 9: 163-175, 2009.
21. Radestock Y, Willing C, Kehlen A, Hoang-Vu C and Hombach-Klonisch S: Relaxin enhances S100A4 and promotes growth of human thyroid carcinoma cell xenografts. Mol Cancer Res 8: 494-506, 2010.
22. Ohleth KM, Lenhart JA, Ryan PL, Radecki SV and Bagnell CA: Relaxin increases insulin-like growth factors (IGFs) and IGF-binding proteins of the pig uterus in vivo. Endocrinology 138: 3652-3658, 1997. (Pubitemid 27351913)
23. Klonisch T, Bialek J, Radestock Y, Hoang-Vu C and Hombach- Klonisch S: Relaxin-like ligand-receptor systems are autocrine/ paracrine effectors in tumor cells and modulate cancer progression and tissue invasiveness. Adv Exp Med Biol 612: 104-118, 2007.
24. Kamat AA, Feng S, Agoulnik IU, et al.: The role of relaxin in endometrial cancer. Cancer Biol Ther 5: 71-77, 2006. (Pubitemid 43234981)
25. Hsu SY, Nakabayashi K, Nishi S, et al.: Relaxin signaling in reproductive tissues. Mol Cell Endocrinol 202: 165-170, 2003. (Pubitemid 36593408)
26. Kern A, Agoulnik AI and Bryant-Greenwood GD: The low-density lipoprotein class A module of the relaxin receptor (leucine-rich repeat containing G-protein coupled receptor 7): its role in signaling and trafficking to the cell membrane. Endocrinology 148: 1181-1194, 2007.
27. Kern A, Hubbard D, Amano A and Bryant-Greenwood GD: Cloning, expression, and functional characterization of relaxin receptor (leucine-rich repeat-containing G protein-coupled receptor 7) splice variants from human fetal membranes. Endocrinology 149: 1277-1294, 2008. (Pubitemid 351397972)
28. Radestock Y, Hoang-Vu C and Hombach-Klonisch S: Relaxin downregulates the calcium binding protein S100A4 in MDA-MB- 231 human breast cancer cells. Ann N Y Acad Sci 1041: 462-469, 2005. (Pubitemid 41132287)